Metagenomi Inc (MGX) Actualités

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Metagenomi to Present at the 2024 Jefferies Global Healthcare Conference

EMERYVILLE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic...

Form 8-K - Current report

Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results

Late breaking presentation at World Federation of Hemophilia (WFH) World Congress on investigational...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems

EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic...

Metagenomi to Present at Upcoming Scientific Meetings

-   Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024 -   Two Posters at...

Metagenomi Reports Business Updates and Full Year 2023 Financial Results

Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development...

Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference

EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Metageno­mi, Inc. (Nas­daq: MGX), a pre­ci­sion...

Metagenomi Announces Closing of Initial Public Offering

EMERYVILLE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic...

Metagenomi Announces Pricing of Initial Public Offering

EMERYVILLE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (“Metagenomi”...